Modeling of Tumor Control Probability in Stereotactic Body Radiation Therapy for Adrenal Tumors

Purpose: Stereotactic body radiation therapy (SBRT) in the management of adrenal metastases is emerging as a well-tolerated, effective method of treatment for patients with limited metastatic disease. SBRT planning and treatment utilization are widely variable, and publications report heterogeneous radiation dose fractionation schemes and treatment outcomes. The objective of this analysis was to review the current literature on SBRT for adrenal metastases and to develop treatment guidelines and a model for tumor control probability of SBRT for adrenal metastases based on these publications. Methods and Materials: A literature search of all studies on SBRT for adrenal metastases published from 2008 to 2017 was performed, and outcomes in these studies were reviewed. Local control (LC) rates were fit to a statistically significant Poisson model using maximum likelihood estimation techniques. Results: One-year LC greater than 95% was achieved at an approximated biological equivalent dose with alpha/beta = 10 Gy of 116.4 Gy. Conclusions: While respecting normal tissue tolerances, tumor doses greater than or equal to a biological equivalent dose with alpha/beta = 10 Gy of 116.4 Gy are recommended to achieve high LC. Further studies following unified reporting standards are needed for more robust prediction. Published by Elsevier Inc.

Automated summary

This study reviewed literature on SBRT for adrenal metastases published from 2008 to 2017, and developed treatment guidelines and a tumor control probability model based on the findings. The research recommended tumor doses greater than or equal to 116.4 Gy (α/β = 10 Gy) for achieving high LC rates, while further studies following unified reporting standards are needed for more robust prediction.